

4. **Menendez R**, Torres A, Zalacain R, *et al*. Risk factors of treatment failure in community acquired pneumonia: implications for disease outcome. *Thorax* 2004;**59**:960–5.
5. **Roson B**, Carratala J, Fernandez-Sabe N, *et al*. Causes and factors associated with early failure in hospitalized patients with community-acquired pneumonia. *Arch Intern Med* 2004;**164**:502–8.
6. **Deng JC**, Standiford TJ. The systemic response to lung infection. *Clin Chest Med* 2005;**26**:1–9.
7. **Nelson S**. Novel nonantibiotic therapies for pneumonia: cytokines and host defense. *Chest* 2001;**119**(2 Suppl):419S–25.
8. **Skerrett SJ**, Park DR. Anti-inflammatory treatment of acute and chronic pneumonia. *Semin Respir Infect* 2001;**16**:76–84.
9. **Waterer GW**, Wunderink RG. Genetic susceptibility to pneumonia. *Clin Chest Med* 2005;**26**:29–38.
10. **Hedlund J**, Hansson LO. Procalcitonin and C-reactive protein levels in community-acquired pneumonia: correlation with etiology and prognosis. *Infection* 2000;**28**:68–73.
11. **Polzin A**, Pletz M, Erbes R, *et al*. Procalcitonin as a diagnostic tool in lower respiratory tract infections and tuberculosis. *Eur Respir J* 2003;**21**:939–43.
12. **Ioannas M**, Ferrer M, Cavalcanti M, *et al*. Causes and predictors of nonresponse to treatment of intensive care unit-acquired pneumonia. *Crit Care Med* 2004;**32**:938–45.
13. **Luyt CE**, Guerin V, Combes A, *et al*. Procalcitonin kinetics as a prognostic marker of ventilator-associated pneumonia. *Am J Respir Crit Care Med* 2005;**171**:48–53.
14. **Smith RP**, Lipworth BJ, Cree IA, *et al*. C-reactive protein. A clinical marker in community-acquired pneumonia. *Chest* 1995;**108**:1288–91.
15. **Fine MJ**, Auble TE, Yealy DM, *et al*. A prediction rule to identify low-risk patients with community-acquired pneumonia. *N Engl J Med* 1997;**336**:243–50.
16. **Dellinger RP**, Carlet JM, Masur H, *et al*. Surviving sepsis campaign guidelines for management of severe sepsis and septic shock. *Crit Care Med* 2004;**32**:858–73.
17. **Halm EA**, Fine MJ, Marrie TJ, *et al*. Time to clinical stability in patients hospitalized with community-acquired pneumonia: implications for practice guidelines. *JAMA* 1998;**279**:1452–7.
18. **Mandell LA**, Wunderink RG, Anzueto A, *et al*. IDSA/ATS consensus guidelines on the management of community-acquired pneumonia. *Clin Infect Dis* 2007;**44**(Suppl 2):S27–72.
19. **Ewig S**, Ruiz M, Mensa J, *et al*. Severe community-acquired pneumonia. Assessment of severity criteria. *Am J Respir Crit Care Med* 1998;**158**:1102–8.
20. **Malcolm C**, Marrie TJ. Antibiotic therapy for ambulatory patients with community-acquired pneumonia in an emergency department setting. *Arch Intern Med* 2003;**163**:797–802.
21. **Povoa P**, Coelho L, Almeida E, *et al*. C-reactive protein as a marker of ventilator-associated pneumonia resolution: a pilot study. *Eur Respir J* 2005;**25**:804–12.
22. **Antunes G**, Evans SA, Lordan JL, *et al*. Systemic cytokine levels in community-acquired pneumonia and their association with disease severity. *Eur Respir J* 2002;**20**:990–5.
23. **Boussekey N**, Leroy O, Alfandari S, *et al*. Procalcitonin kinetics in the prognosis of severe community-acquired pneumonia. *Intensive Care Med* 2006;**32**:469–72.
24. **Harbarth S**, Holeckova K, Froidevaux C, *et al*. Diagnostic value of procalcitonin, interleukin-6, and interleukin-8 in critically ill patients admitted with suspected sepsis. *Am J Respir Crit Care Med* 2001;**164**:396–402.
25. **Masia M**, Gutierrez F, Shum C, *et al*. Usefulness of procalcitonin levels in community-acquired pneumonia according to the patients outcome research team pneumonia severity index. *Chest* 2005;**128**:2223–9.
26. **Prat C**, Dominguez J, Andreo F, *et al*. Procalcitonin and neopterin correlation with aetiology and severity of pneumonia. *J Infect* 2006;**52**:169–77.
27. **Monton C**, Torres A, El-Ebary M, *et al*. Cytokine expression in severe pneumonia: a bronchoalveolar lavage study. *Crit Care Med* 1999;**27**:1745–53.
28. **Monton C**, Ewig S, Torres A, *et al*. Role of glucocorticoids on inflammatory response in nonimmunosuppressed patients with pneumonia: a pilot study. *Eur Respir J* 1999;**14**:218–20.
29. **Confalonieri M**, Urbino R, Potena A, *et al*. Hydrocortisone infusion for severe community-acquired pneumonia: a preliminary randomized study. *Am J Respir Crit Care Med* 2004;**169**:19.
30. **Christ-Crain M**, Stolz D, Bingisser R, *et al*. Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. *Am J Respir Crit Care Med* 2006;**174**:84–93.
31. **Nelson S**, Bagby GJ, Dale D. Cytokine treatment of bacterial pneumonia. *Semin Respir Infect* 2001;**16**:38–46.
32. **Moore TA**, Standiford TJ. Cytokine immunotherapy during bacterial pneumonia: from benchtop to bedside. *Semin Respir Infect* 2001;**16**:27–37.

Lung alert

Snoring is more strongly associated with chronic bronchitis in non-smokers

It has been suggested that patients with chronic bronchitis are more likely to snore during sleep. The authors studied 5015 people in Korea aged 40–69 years who all participated in a comprehensive health examination and on-site interview. Participants who reported symptoms suggesting chronic bronchitis or a previous diagnosis of chronic obstructive pulmonary disease who did not complete questions related to snoring, whose smoking status was not reported or who reported pregnancy during follow-up were excluded.

A total of 4270 participants (52% men) entered the analysis for the first 2 years. Participants were asked about the presence and frequency of snoring. Baseline demographic data showed that frequent snorers were more likely to be older, male, working, heavier, alcohol-consuming smokers and with a history of exposure to chemicals.

During a 4-year follow-up period, 314 new cases (27.1 cases per 1000 person-years) of chronic bronchitis were identified. Follow-up of these patients showed that snoring frequency had a positive linear relationship with the risk of chronic bronchitis. Stratified analysis by smoking showed an association between snoring and chronic bronchitis in never smokers, while a non-significant association was seen in former and current smokers. A similar significant association between snoring and chronic bronchitis was observed among house workers, which was probably related to the association seen in non-smokers since most house workers studied were non-smoking women.

This study provides support for the hypothesis that snoring is associated with chronic bronchitis. As the study did not explore the mechanism of how snorers may develop chronic bronchitis, further investigation is needed to determine the link between these conditions.

► Baik I, Kim J, Abbott RD, *et al*. Association of snoring with chronic bronchitis. *Arch Intern Med* 2008;**168**:167–73.

Ghassan Elsayed

Correspondence to: Dr G Elsayed, Department of Respiratory Medicine, Homerton University Hospital, London, UK; ghassanovii@yahoo.co.uk